

BIOPRODUCTIONSUMMIT

Agenda Day 1 - September 21



9:00 - 11:45

SESSION I: High Yielding AAV Platforms for Gene Therapy

9:00 AM - 9:15 AM

Chairperson's Opening Remarks

Nicole Paulk, Assistant Professor of AAV Gene Therapy

UCSF

9:15 AM - 9:45 AM

AAV Vectors: From Discovery to Large Scale Clinical Manufacturing, an Academic Story

Nathalie Clement, Associate Director of Vector Manufacturing

UF Powell Gene Therapy Center

9:45 AM - 10:15 AM

Generation of Producer Cell Lines, a Stable Helper-Virus Free AAV Production Technology

Kerstein Hein, Head of Viral Vectors

CEVEC

10:15 AM - 10:45 AM

Novel Scalable Strategies for AAV Manufacture

Alissa Bray, Senior Scientist

OXGENE

10:45 AM - 11:15 AM

Rapid CMC Development and Pre-Commercial Considerations for rAAV Gene Therapy Products for Rare Diseases

James Warren, VP of Pharmaceutical Development

UltraGenyx

11:15 AM - 11:45 AM


Panel Discussion and Q & A

11:45 AM - 12:15 PM

BREAK

BIOPRODUCTION **SUMMIT**

Agenda Day 1 - September 21

 12:00 - 3:30

SESSION II: Advances in Large Scale AAV
Manufacturing for Gene Therapy

12:15 PM – 12:30 PM

Chairperson's Opening Remarks

Don Jarvis, Professor of Molecular Biology, University of Wyoming & President

Glycobac LLC

12:30 PM – 1:00 PM

Manufacturing Considerations for Successful Gene Therapy Development

Emma Bjorgum, Director of Client Development, GMP Nucleic Acids

Aldevron

1:00 PM – 1:30 PM

Making Gene Therapy Affordable and Accessible

Audrey Greenberg, Co-founder and Executive Managing Director

The Discovery Labs

1:30 PM – 2:00 PM

Next-Generation Transfection Reagent for Large Scale AAV Manufacturing

Mathieu Porte, Bioproduction R&D Manager

Polyplus Transfection

2:00 PM – 2:30 PM

An Sf-Rhabdovirus – negative insect cell line for producing AAV Vectors and monitoring Sf-Rhabdovirus contamination

Don Jarvis, Professor of Molecular Biology, University of Wyoming & President

Glycobac LLC

2:30 PM – 3:00 PM

Panel Discussion and Q & A

3:00 PM – 3:30 PM

BREAK

BIOPRODUCTION SUMMIT

Agenda Day 1 - September 21



3:30 - 6:00

SESSION III: Technology Advances in
Bioprocessing for Biologics Manufacturing

3:30 PM - 3:45 PM

Chairperson's Opening Remarks

Parviz Shamalou, Founding Executive Director

Jefferson Institute of Bioprocessing

3:45 PM - 4:15 PM

Global technology and Innovation

Samet Yildirim, Head of Global Technology and Innovation

Boehringer Ingelheim

4:15 PM - 4:45 PM

Celltheon SMART Platform for the expression of Difficult to Express Proteins

Divya Goel, Vice President Business Development

Celltheon

4:45 PM - 5:15 PM

Customization of Workflows to enable High- throughput Transient Protein Expression from a CHO Manufacturing Cell Line

Sarah Rue, Associate Director, Advanced Automation Technologies

Genomics Institute of The Novartis Research Foundation

5:15 PM - 5:45 PM

Title TBA

Parviz Shamalou, Founding Executive Director

Jefferson Institute of Bioprocessing

5:45 PM - 6:00 PM


Panel Discussion and Q & A

6:00 PM

END OF DAY 1

BIOPRODUCTIONSUMMIT

Agenda Day 2 - September 22

 9:00 - 11:45

SESSION IV: Novel AAV Capsids For Gene Therapy
- Discovery, Characterization and Manufacturing

9:00 AM - 9:15 AM

Chairperson's Opening Remarks

Nicole Paulk, Assistant Professor of AAV Gene Therapy

UCSF

9:15 AM - 9:45 AM

Integration of Engineered AAVs with CRISPR for Gene Therapy and Genome Editing Applications

David Schaffer, Director of The Berkeley Stem Cell Center

UC Berkeley

9:45 AM - 10:15 AM

Genomics and Proteomics of AAV Manufacturing

Nicole Paulk, Assistant Professor of AAV Gene Therapy

UCSF

10:15 AM - 10:45 AM

AAV Vectors from Discovery to Clinical Use: A REGENXBIO Experience

Olivier Danos, Chief Scientific Officer

REGENXBIO

10:45 AM - 11:15 AM

AI-powered Design of Synthetic AAV Capsids

Eric Kelsic, Chief Executive Officer

Dyno Therapeutics

11:15 AM - 11:45 AM

Panel Discussion and Q & A

11:45 AM - 12:15 PM

BREAK

BIOPRODUCTION SUMMIT

Agenda Day 2 - September 22

🕒 12:15 - 5:00

SESSION V: Industry perspective, CMC and Commercialization Challenges for Gene & Cell Therapy

12:15 PM – 12:30 PM

Chairperson's Opening Remarks

Lucas De Breed, Founder and Managing Director

August

12:30 PM – 1:00 PM

KOL Perspectives on Challenges, Advances, and Future Opportunities in AAV Gene Therapies

Susan Zhou, Senior Associate

DeciBio Consulting

1:00 PM – 1:30 PM

Overview of Gene Therapy Commercialization Landscape

Lucas De Breed, Founder and Managing Director

August

1:30 PM – 2:00 PM

Non Viral Delivery of ZFN mRNA enables highly efficient in vivo genome editing for multiple therapeutic gene targets

Anthony Conway, Associate Director of Cell Therapy

Sangamo Therapeutics

2:00 PM – 2:30 PM

Overcoming Key Hurdles in the Age of Patient Scale Cell Therapy Commercialization

Eytan Abraham, Head of Personalized Medicine

Lonza

2:30 PM – 3:00 PM

Reimagining Biomanufacturing Through the Lens of Systems Thinking

Philip G. Vanek, CTO & Partner

Gamma Biosciences

3:00 PM - 3:30 PM

Understanding the bioproduction and material requirements to support timely gene therapy AAV clinical assay and companion diagnostic development, and commercialization

Karen L. Richards & Travis Harrison

Precision for Medicine

3:30 PM – 4:00 PM

Panel Discussion and Q & A

4:00 PM

End of Conference!